Achilles Therapeutics plc (ACHL)
NASDAQ: ACHL · Real-Time Price · USD
0.981
-0.005 (-0.49%)
At close: Dec 20, 2024, 4:00 PM
0.980
-0.001 (-0.11%)
After-hours: Dec 20, 2024, 4:40 PM EST
Achilles Therapeutics Employees
As of December 31, 2023, Achilles Therapeutics had 215 total employees, including 204 full-time and 11 part-time employees. The number of employees decreased by 27 or -11.16% compared to the previous year.
Employees
215
Change (1Y)
-27
Growth (1Y)
-11.16%
Revenue / Employee
n/a
Profits / Employee
-$311,065
Market Cap
40.32M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 215 | -27 | -11.16% |
| Dec 31, 2022 | 242 | -10 | -3.97% |
| Dec 31, 2021 | 252 | 93 | 58.49% |
| Dec 31, 2020 | 159 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| FibroGen | 486 |
| Neuronetics | 203 |
| CASI Pharmaceuticals | 176 |
| Enzo Biochem | 136 |
| Passage Bio | 58 |
| Actinium Pharmaceuticals | 49 |
| Gain Therapeutics | 32 |
ACHL News
- 4 weeks ago - Achilles Therapeutics Receives Approval to Transfer to Nasdaq Capital Market - GlobeNewsWire
- 5 weeks ago - Achilles Therapeutics Reports Third Quarter 2024 Financial Results - GlobeNewsWire
- 3 months ago - Achilles Therapeutics Announces Strategic Update - GlobeNewsWire
- 4 months ago - Achilles Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Updates - GlobeNewsWire
- 7 months ago - Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines - GlobeNewsWire
- 7 months ago - Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement - GlobeNewsWire
- 8 months ago - Achilles Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights - GlobeNewsWire
- 9 months ago - Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights - GlobeNewsWire